Kynurenine Pathway Dysregulation in Parkinson's Disease: Insights for Disease Modulation and Therapy

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Parkinson's disease (PD) is a prevalent neurodegenerative disorder affecting millions globally.
• Neuroinflammation, driven by microglia activation and inflammatory mediators, plays a key role in PD pathogenesis.
• The kynurenine pathway (KP) significantly modulates immune responses in Parkinsonism, producing both neurotoxic and neuroprotective compounds.

Purpose of the Study:

• To investigate the therapeutic potential of modulating the kynurenine pathway (KP) for Parkinson's disease (PD).
• To explore the use of pharmacological agents targeting KP enzymes as a novel treatment strategy for PD.
• To assess the utility of KP metabolites as predictive biomarkers for PD.

Main Methods:

• Review of previous studies on the role of the kynurenine pathway (KP) in Parkinson's disease (PD).
• Analysis of research investigating the effects of drug treatments on KP enzymes.
• Examination of the neurotoxic and neuroprotective mechanisms associated with KP metabolites.

Main Results:

• The kynurenine pathway (KP) involves the production of neurotoxic (e.g., quinolinic acid from microglia) and neuroprotective (e.g., kynurenic acid from astrocytes) compounds.
• Modulation of KP enzymes has demonstrated potential in preventing neurodegeneration in preclinical studies.
• Pharmacological inhibition of KP enzymes is a viable therapeutic avenue for PD.

Conclusions:

• Targeting the kynurenine pathway (KP) presents a novel therapeutic approach for Parkinson's disease (PD).
• Pharmacological modulators of KP enzymes could offer a new treatment strategy for PD.
• KP metabolites show promise as predictive biomarkers for Parkinson's disease (PD).